US Patent

US7816404 — Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions

Method of Use · Assigned to Rockwell Medical Technologies Inc · Expires 2029-04-17 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for preparing and using a highly water-soluble ferric pyrophosphate citrate chelate composition for treating iron deficiency.

USPTO Abstract

A highly water soluble ferric pyrophosphate citrate chelate useful for treating iron deficiency contains 2% or less phosphate by weight. These chelate compositions are easily milled and/or processed into dosage forms using conventional techniques, and are expected to exhibit advantageous biocompatibility as compared to conventional soluble ferric pyrophosphates, ferric salts, ferric polysaccharide complexes and ferrous salts.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1656 — Triferic
U-1656 — Triferic
U-2801 — Triferic

Patent Metadata

Patent number
US7816404
Jurisdiction
US
Classification
Method of Use
Expires
2029-04-17
Drug substance claim
No
Drug product claim
Yes
Assignee
Rockwell Medical Technologies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.